Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANXENE SD vs XANAX XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal inhibition.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability.
Anxiety disorders,Short-term relief of anxiety symptoms,Acute alcohol withdrawal,Preoperative sedation (adjunctive),Partial seizures (adjunctive, off-label)
Panic disorder with or without agoraphobia
Oral: 11.25-22.5 mg once daily (sustained-release formulation).
0.5-1 mg orally once daily; may increase at 3-4 day intervals; maximum 10 mg/day
Terminal elimination half-life of nordazepam (active metabolite) is 30–100 hours (mean 50 hours); clorazepate itself has a short half-life (~2 hours) due to rapid conversion.
Mean terminal elimination half-life is 11.2 hours (range 6.3-15.8 hours). The extended-release formulation provides sustained therapeutic concentrations with once-daily dosing.
Hepatic via conjugation and oxidative metabolism; primary metabolite is desmethyldiazepam (active); CYP450 involvement (CYP3A4 and CYP2C19).
Hepatic via CYP3A4; active metabolite alprazolam does not accumulate significantly.
Renal excretion of conjugated metabolites, with less than 1% unchanged drug; approximately 30% excreted in feces via biliary elimination.
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of the dose. Fecal excretion is minimal (<10%).
97–98% bound to albumin; nordazepam is highly protein-bound.
80% bound to serum albumin.
0.9–1.4 L/kg for clorazepate; nordazepam Vd approximately 0.8–1.2 L/kg, indicating extensive tissue distribution.
Approximately 1.1 L/kg (range 0.9-1.3 L/kg), indicating extensive tissue distribution.
Oral: 100% (prodrug fully converted); no parenteral formulation.
Oral: Approximately 90% (absolute bioavailability).
GFR <10 m L/min: Reduce dose by 25-50% and consider avoidance due to accumulation of active metabolites.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: initiate at 0.5 mg once daily, titrate cautiously; GFR <15 m L/min: avoid use
Child-Pugh Class B or C: Reduce dose by 50% or avoid use; monitor for excessive sedation.
Child-Pugh Class A: initiate 0.5 mg once daily; Child-Pugh Class B: initiate 0.25 mg once daily; Child-Pugh Class C: avoid use
Not recommended for patients <18 years due to lack of safety and efficacy data.
Not FDA approved for patients <18 years; off-label doses: 0.125-0.5 mg/kg/day divided once daily; titrate slowly
Reduce initial dose by 50% (e.g., 11.25 mg once daily or less), titrate slowly, and monitor for falls and cognitive impairment.
Initiate 0.25 mg once daily; titrate by 0.125 mg increments every 3-4 days; maximum 2 mg/day
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death; reserve for patients with inadequate alternative treatment options.
Risk of abuse, misuse, and addiction,Dependence and withdrawal reactions,CNS depressant effects (impairment of driving/operating machinery),Respiratory depression (especially with opioids),Glaucoma (narrow-angle) use cautiously,Suicidal ideation (pre-existing depression)
Risks of dependence and withdrawal reactions,Risk of abuse and misuse,Concomitant use with CNS depressants,Risk of severe anaphylactic reactions,Use in patients with depression or suicidal ideation
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concomitant use with opioids (in some contexts)
Hypersensitivity to alprazolam or other benzodiazepines,Concurrent use with ketoconazole or itraconazole,Acute narrow-angle glaucoma
Food may delay but does not significantly reduce absorption. Avoid grapefruit juice as it may inhibit CYP3A4, increasing nordazepam levels. Avoid alcohol completely.
Grapefruit and grapefruit juice may increase alprazolam levels; avoid concurrent consumption. Alcohol intake should be strictly avoided due to additive CNS depressant effects. Take with or without food; however, high-fat meals may delay absorption but not the extent.
First trimester: Increased risk of congenital malformations (oral clefts) reported with benzodiazepine use; data specifically for clorazepate limited but class effect assumed. Second/third trimester: Exposure may cause fetal CNS depression, hypotonia, respiratory depression, and withdrawal symptoms (e.g., jitteriness, hypertonia) in neonates.
First trimester: Increased risk of oral cleft (absolute risk 0.5-1% vs 0.1-0.2% background). Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, respiratory depression, and neonatal sedation. Late third trimester or delivery: Risk of neonatal withdrawal and hypotonia.
Clorazepate is excreted into breast milk; M/P ratio approximately 0.2. Infant exposure likely low but may cause sedation. Use with caution; monitor infant for drowsiness and poor feeding. Consider alternative if high maternal doses or prolonged use.
Alprazolam is excreted in breast milk. M/P ratio approximately 0.36. Monitor infant for sedation, poor feeding, and weight gain. Use lowest effective dose and consider alternative agents if prolonged use required.
Increased volume of distribution and enhanced hepatic metabolism in pregnancy may lower serum clorazepate levels; consider dose increase if therapeutic effect inadequate. Avoid in first trimester if possible; use lowest effective dose in later trimesters. Taper gradually before delivery to minimize neonatal withdrawal.
Increased clearance and decreased half-life in pregnancy may require dose increase. Titrate to clinical effect. Avoid use in labor due to neonatal depression risk.
TRANXENE SD (clorazepate dipotassium) is a long-acting benzodiazepine with a slow onset, making it less suitable for acute panic but effective for generalized anxiety. Its active metabolite, nordazepam, has a half-life of 40-100 hours, allowing once-daily dosing. Monitor for accumulation in elderly or hepatic impairment. Use with caution in patients with a history of substance abuse due to dependence risk.
XANAX XR (alprazolam extended-release) is indicated for panic disorder with or without agoraphobia. Due to its extended-release formulation, it has a slower onset and longer duration compared to immediate-release alprazolam. Dose conversion from immediate-release is not 1:1; total daily dose of immediate-release should be given once daily of XR. Avoid abrupt discontinuation to prevent withdrawal symptoms, including seizures. Monitor for CNS depression when co-administered with other CNS depressants. Use cautiously in patients with hepatic impairment or elderly due to reduced clearance.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop abruptly; reduce dose gradually to avoid withdrawal symptoms (e.g., anxiety, insomnia, seizures).,Avoid alcohol and other CNS depressants (e.g., opioids, sedatives) as they increase sedation and respiratory depression risk.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how the drug affects you.,Report any unusual changes in mood, thoughts, or behavior (e.g., depression, suicidal thoughts).,Use effective contraception if of childbearing potential due to fetal harm risk; notify prescriber if pregnant or breastfeeding.
Take this medication exactly as prescribed, usually once daily in the morning.,Do not crush, chew, or break the extended-release tablets; swallow them whole.,Avoid alcohol and other CNS depressants while taking XANAX XR, as they can increase drowsiness and risk of overdose.,Do not stop taking this medication abruptly without consulting your doctor; withdrawal symptoms can occur.,This medication can be habit-forming; use only as directed and do not share with others.,Inform your doctor if you become pregnant or plan to become pregnant, as use during pregnancy may harm the fetus.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANXENE SD vs XANAX XR, answered by our medical review team.
TRANXENE SD is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal inhibition.. XANAX XR is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANXENE SD and XANAX XR depend on the specific clinical indication. These are both Benzodiazepine Anxiolytic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANXENE SD is: Oral: 11.25-22.5 mg once daily (sustained-release formulation).. The standard adult dose of XANAX XR is: 0.5-1 mg orally once daily; may increase at 3-4 day intervals; maximum 10 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANXENE SD and XANAX XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANXENE SD is classified as Category C. First trimester: Increased risk of congenital malformations (oral clefts) reported with benzodiazepine use; data specifically for clorazepate limited but class effect assumed. Seco. XANAX XR is classified as Category C. First trimester: Increased risk of oral cleft (absolute risk 0.5-1% vs 0.1-0.2% background). Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, respi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.